Eli Lilly And Co vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Eli Lilly And Co trades at $1,162.76 (market cap $1.02T), while Invesco S&P 500 High Div Low Volatility ETF trades at $52.11. The key difference: Eli Lilly And Co pays a 0.6% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none. Which is the better fit depends on your goals.
| LLY | SPHD | |
|---|---|---|
Market Cap | $1.02T | — |
Sector | Health | — |
52-Week High | $1.24K | $53.18 |
52-Week Low | $625.65 | $46.96 |
Enterprise Value | $1.06T | — |
Dividend Yield | 0.6% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
SPHD trades at $52.39, down 0.91% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering a 4.5% yield with monthly distributions. Recent news highlights its defensive appeal for retirees seeking stable income amid market uncertainty, though it has underperformed the broader S&P 500 historically.
Outlook remains cautious; SPHD provides income stability but faces growth limitations. Risks include interest rate sensitivity and sector concentration. Analyst sentiment is mixed, with upgrades citing defensive positioning but noting long-term performance gaps versus the market.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →